Regeneron Gets FDA, EMA Review of Cemdisiran in Generalized Myasthenia Gravis
By Colin Kellaher
Regeneron Pharmaceuticals said U.S. and European regulators have accepted its applications seeking approval of its cemdisiran drug candidate in the rare and chronic autoimmune disease generalized myasthenia gravis, or gMG.
Regeneron on Monday said the U.S. Food and Drug Administration and the European Medicines Agency will review cemdisiran to for adults with gMG who are anti-acetylcholine receptor antibody-positive.
The Tarrytown, N.Y., biotechnology company said the FDA has granted the application priority review, which shortens the review period, and that it set a target action date in November.
Regeneron, which is developing cemdisiran under a licensing agreement with Alnylam Pharmaceuticals, said it expects a decision from the European Commission in the second half of 2027.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 22, 2026 07:48 ET (11:48 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States